The effect of microdosing have been overstated, at least when it comes to depression.

A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression.

The study has not yet been published. But MindBio’s CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was “in front of the curve in microdosing research.”

  • quips@slrpnk.netEnglish
    11·
    2 days ago

    In my anecdotal experience, when I’ve done shrooms the depression benefits feel like they came not so much from the chemical itself but from the mindset it puts you in. That perspective, combined with the plastic state shrooms put you in has felt the most useful.

    It allows you to reevaluate your life and gain perspective on it, while that plasticity actually lets those things stick.

    When you microdose sure you might see some of those benefits, but you don’t really enter that altered state of mind where, imo, the real benefits come from.

    This is why I think therapy guided sessions are likely the future of psychedelic treatment for mental illnesses like depression.